American Thoracic Society - Sanofi Investor Call

E-RS: COPD Total Score LS mean change ± 95% CI 0.2 -0.2 -0.6- Patient-Reported Outcomes: Symptoms (E-RS: COPD) Placebo Dupilumab -1.0- -1.4- -1.8 -2.2- -2.6- -3.0- -3.4 TT 01234 8 12 24 Week 36 44 467 454 448 443 Dupilumab 461 446 435 439 No. of participants with observed change from baseline Placebo 424 428 ATS 2023 52 42 414 404 379 412 403 380 Week 52 LS mean difference (95% CI) -1.1 (-1.8 to -0.4) P=0.001 Lower score indicates less severe respiratory symptoms 29

View entire presentation